, Carcinome hépatocellulaire (cancer primitif du foie) | SNFGE.org -Société savante médicale française d'hépato-gastroentérologie et d'oncologie digestive
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol. janv, vol.10, issue.1, pp.25-34, 2009. ,
,
, Saturable absorption of sorafenib in patients with solid tumors: a population model, Invest New Drugs, vol.30, issue.5, pp.1991-2000, 2012.
Sorafenib in advanced hepatocellular carcinoma, N Engl J Med. 24 juill, vol.359, issue.6, pp.378-90, 2008. ,
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer. 1 mars, vol.136, issue.5, pp.359-386, 2015. ,
Comment améliorer le dépistage de l'Hépatocarcinome, p.10 ,
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer, Nat Rev Drug Discov, vol.5, issue.5, pp.835-879, 2006. ,
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial, Lancet Lond Engl. 24 mars, vol.391, pp.1163-73, 2018. ,
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia, Blood. 15 avr, vol.109, issue.8, pp.3496-3505, 2007. ,
) Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis, The Oncologist, vol.17, issue.2, pp.1204-1216, 2012. ,
,
, Sorafenib in advanced melanoma: a critical role for pharmacokinetics?, Br J Cancer. 24 juill, vol.107, issue.3, pp.455-61, 2012.
Hepatocellular carcinoma: increasing incidence and optimized management ,
, Gastroenterol Clin Biol. sept, vol.33, issue.8-9, pp.830-839, 2009.
, Trinchet -2009 -[Hepatocellular carcinoma increasing incidence an.pdf
,
, Radiol. juill, vol.54, issue.7, pp.654-663, 2014.
, European Association for Study of Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma, Eur J Cancer Oxf Engl, vol.48, issue.5, pp.599-641, 1990.
, N Engl J Med. 22 sept, vol.365, issue.12, pp.1118-1145, 2011.
Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. août, vol.5, issue.8, pp.1-4, 2007. ,
Hepatocellular carcinoma in cirrhosis: incidence and risk factors, Gastroenterology, vol.127, issue.5, pp.35-50, 2004. ,
Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era, World J Gastroenterol WJG. 21 mars, vol.14, issue.11, pp.1657-63, 2008. ,
Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis, Semin Liver Dis. févr, vol.30, issue.1, pp.3-16, 2010. ,
Genetic Landscape and Biomarkers of Hepatocellular Carcinoma, Gastroenterology. oct, vol.149, issue.5, pp.1226-1239, 2015. ,
Natural history and treatment of chronic delta hepatitis, J Viral Hepat, vol.17, issue.11, pp.749-56, 2010. ,
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level, JAMA. 4 janv, vol.295, issue.1, pp.65-73, 2006. ,
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications, Gastroenterology, vol.152, issue.1, pp.142-156, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01447065
New advances in hepatocellular carcinoma, World J Hepatol. 28 mars, vol.8, issue.9, pp.421-459, 2016. ,
Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatol Baltim Md, vol.36, pp.1206-1219, 2002. ,
Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma, World J Hepatol. 28 août, vol.7, issue.18, pp.2155-61, 2015. ,
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study, Hepatol Baltim Md. mars, vol.63, issue.3, pp.827-865, 2016. ,
A review of molecular mechanisms in the development of hepatocellular carcinoma by aflatoxin and hepatitis B and C viruses, J Environ Pathol Toxicol Oncol Off Organ Int Soc Environ Toxicol Cancer, vol.32, issue.2, pp.165-75, 2013. ,
Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma, J Hepatol. févr, vol.42, issue.2, pp.218-242, 2005. ,
Mediterranean diet and hepatocellular carcinoma, J Hepatol. mars, vol.60, issue.3, pp.606-617, 2014. ,
Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies, Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP, vol.26, issue.5, pp.368-77, 2017. ,
Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis ,
, Gastroenterology. févr, vol.144, issue.2, pp.323-355, 2013.
Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis, J Clin Endocrinol Metab. juill, vol.97, issue.7, pp.2347-53, 2012. ,
Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis, Cancer Prev Res Phila Pa. août, vol.5, issue.8, pp.1007-1021, 2012. ,
Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review, J Hepatol. août, vol.53, issue.2, pp.348-56, 2010. ,
Management of hepatocellular carcinoma: An update, Hepatol Baltim Md. mars, vol.53, issue.3, pp.1020-1022, 2011. ,
, European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma, J Hepatol. juill, vol.69, issue.1, pp.182-236, 2018.
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial, J Hepatol. sept, vol.43, issue.3, pp.434-475, 2005. ,
Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma, 41. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. The Lancet. 31 mars, vol.47, issue.1, pp.1245-55, 2008. ,
Prognosis of hepatocellular carcinoma: the BCLC staging classification, Semin Liver Dis, vol.19, issue.3, pp.329-367, 1999. ,
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis, N Engl J Med. 14 mars, vol.334, issue.11, pp.693-702, 1996. ,
Liver transplantation for hepatocellular carcinoma: a model including ?-fetoprotein improves the performance of Milan criteria, Gastroenterology, vol.143, issue.4, pp.986-994, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-00865368
Management of hepatocellular carcinoma: An update, Hepatol Baltim Md. mars, vol.53, issue.3, pp.1020-1022, 2011. ,
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival, Hepatology, vol.37, issue.2, pp.429-471, 2003. ,
,
, Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Meta-Analysis of Randomized Controlled Trials1, Radiology [Internet]. 1 juill, 2002.
,
Management of hepatocellular carcinoma. Hepatol Baltim Md, vol.42, pp.1208-1244, 2005. ,
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Lond Engl, vol.07, pp.56-66, 2017. ,
,
, Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial, J Clin Oncol. 1 févr, vol.36, issue.4_suppl, pp.207-207, 2018.
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an openlabel randomised controlled phase 3 trial, Lancet Oncol, vol.18, issue.12, pp.1624-1660, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01727346
Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma, J Clin Oncol Off J Am Soc Clin Oncol. 1 juill, vol.36, issue.19, pp.1913-1934, 2018. ,
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial, Lancet Oncol. juill, vol.16, issue.7, pp.859-70, 2015. ,
REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib, J Clin Oncol. 20 mai, vol.36, issue.15_suppl, pp.4003-4003, 2018. ,
, N Engl J Med, vol.11, issue.15, pp.1450-62, 2019.
Molecular mechanisms of sorafenib action in liver cancer cells, Cell Cycle Georget Tex. 1 août, vol.11, issue.15, pp.2843-55, 2012. ,
Toxicity of sorafenib: clinical and molecular aspects, Expert Opin Drug Saf. mars, vol.9, issue.2, pp.275-87, 2010. ,
Utilisation du sorafénib (Nexavar ® ) dans le traitement du carcinome hépatocellulaire : recommandations Prodige Afef, 2008. ,
,
The Role of Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma: An Update, Hepatol Res Off J Jpn Soc Hepatol. févr, vol.43, issue.2, pp.147-54, 2013. ,
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling, Mol Cancer Ther, vol.7, issue.10, pp.3129-3169, 2008. ,
Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature, Methods Enzymol, vol.407, pp.597-612, 2006. ,
Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5, Cancer Res. 15 déc, vol.66, issue.24, pp.11851-11859, 2006. ,
Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma, J Clin Oncol. 20 mai, vol.26, issue.7, pp.4509-4509, 2008. ,
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study, J Hepatol. déc, vol.65, issue.6, pp.1140-1147, 2016. ,
Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study, Clin Cancer Res, vol.23, issue.19, pp.5720-5728, 2017. ,
Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?, Target Oncol, vol.11, issue.4, pp.565-572, 2016. ,
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis, Ann Oncol Off J Eur Soc Med Oncol. févr, vol.24, issue.2, pp.406-417, 2013. ,
Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score, Aliment Pharmacol Ther, vol.34, issue.10, pp.1193-201, 2011. ,
Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis, Eur J Cancer Oxf Engl, vol.105, pp.1-9, 1990. ,
The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits. Cancer, vol.118, pp.5293-301, 2012. ,
Results of the Phase II randomized French trial PRODIGE 21 comparing sorafenib vs pravastatin vs sorafenib and pravastatin vs best supportive care for the palliative treatment of HCC in CHILD B cirrhotic patients, J Hepatol. 1 avr, vol.68, p.195, 2018. ,
Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells, World J Gastroenterol WJG, vol.15, issue.36, pp.4582-4588, 2009. ,
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial, J Hepatol, vol.64, issue.5, pp.1090-1098, 2016. ,
Sorafenib with versus without concurrent conventional transarterial chemoembolization (cTACE) in patients with advanced hepatocellular carcinoma (HCC): Results from a multicenter, open-label, randomized, controlled phase III STAH trial, J Hepatol. 1 avr, vol.68, p.2, 2018. ,
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial, JAMA, vol.17, issue.19, pp.2154-60, 2010. ,
Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance), J Clin Oncol. 1 févr, vol.34, pp.192-192, 2016. ,
SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma, J Clin Oncol Off J Am Soc Clin Oncol. 20 févr, vol.33, issue.6, pp.559-66, 2015. ,
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, Lancet Gastroenterol Hepatol, vol.3, issue.6, pp.424-456, 2018. ,
Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice, Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. sept, vol.44, issue.9, pp.788-92, 2012. ,
Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis, Int J Clin Pract. mai, vol.68, issue.5, pp.609-626, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01689426
Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis, Gastrointest Cancer Res GCR, vol.4, issue.2, pp.40-44, 2011. ,
,
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis, J Clin Gastroenterol. juin, vol.43, issue.5, pp.489-95, 2009. ,
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies, J Hepatol, vol.67, issue.5, pp.999-1008, 2017. ,
Prognostic Factors in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Retrospective Comparison with Previously Known Prognostic Models, Oncology, vol.80, issue.3-4, pp.167-74, 2011. ,
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib, Aliment Pharmacol Ther, vol.34, issue.8, pp.949-59, 2011. ,
Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice, Am J Clin Oncol. avr, vol.40, issue.2, pp.167-74, 2017. ,
Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma, Hepatol Res Off J Jpn Soc Hepatol, vol.45, issue.10, pp.130-140, 2015. ,
,
, Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score, Eur J Cancer Oxf Engl, vol.86, pp.135-177, 1990.
A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer, Ann Oncol Off J Eur Soc Med Oncol. oct, vol.24, issue.10, pp.2565-70, 2013. ,
Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study, J Gastroenterol Hepatol, vol.29, issue.7, pp.1463-1472, 2014. ,
Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib, The Oncologist. janv, vol.15, issue.1, pp.85-92, 2010. ,
Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma, Oncology, vol.84, issue.1, pp.6-13, 2013. ,
Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis, Gastroenterology. juin, vol.120, issue.7, pp.1763-73, 2001. ,
,
, Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake, J Hepatol. avr, vol.54, issue.4, pp.705-720, 2011.
Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: a meta-analysis of randomized clinical trials, Oncology, vol.88, issue.6, pp.345-52, 2015. ,
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma, Clin Cancer Res. 15 avr, vol.18, issue.8, pp.2290-300, 2012. ,
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma, Cancer, vol.116, issue.19, pp.4590-4596, 2010. ,
Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma: Biomarkers of sorafenib treatment, J Gastroenterol Hepatol, vol.26, issue.11, pp.1604-1615, 2011. ,
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors, J Clin Oncol Off J Am Soc Clin Oncol. 10 févr, vol.23, issue.5, pp.965-72, 2005. ,
Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma, Cancer Sci. 1 janv, vol.99, issue.1, pp.159-65, 2008. ,
Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma, The Oncologist. juill, vol.22, issue.7, pp.780-65, 2017. ,
,
, Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma, Tohoku J Exp Med, vol.237, issue.3, pp.173-82, 2015.
, European Medicines Agency -Find medicine -Nexavar
,
Sorafenib: a review of its use in advanced hepatocellular carcinoma, Drugs, vol.69, issue.2, pp.223-263, 2009. ,
Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry, J Chromatogr B Analyt Technol Biomed Life Sci, vol.1, issue.29, pp.3033-3041, 2010. ,
Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors, Clin Cancer Res. 1 août, vol.11, issue.15, pp.5472-80, 2005. ,
Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice, J Pharm Biomed Anal. 1 mai, vol.49, issue.4, pp.1109-1123, 2009. ,
Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma, J Pharm Biomed Anal. 22 janv, vol.46, issue.2, pp.362-369, 2008. ,
Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors, The Oncologist. 1 avr, vol.12, issue.4, pp.426-463, 2007. ,
Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study, PLoS ONE, vol.13, issue.2012 ,
, Disponible sur
Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma ,
, Cancer Chemother Pharmacol. 1 juill, vol.72, issue.1, pp.269-72, 2013.
Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma, Invest New Drugs. 1 déc, vol.29, issue.13, pp.1511-1515, 2011. ,
High throughput routine determination of 17 tyrosine kinase inhibitors by LC-MS/MS, J Pharm Biomed Anal. févr, vol.150, pp.112-132, 2018. ,
Meta-analysis of dermatological toxicities associated with sorafenib, Clin Exp Dermatol. juin, vol.36, issue.4, pp.344-50, 2011. ,
Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps, Cancer Biol Ther. juill, vol.4, issue.7, pp.747-52, 2005. ,
, Étude de l'Association entre la Concentration plasmatique, la Tolérance et l'Efficacité du sorafénib, chez les patients débutant un traitement palliatif pour carcinome hépatocellulaire
Le recueil des EI était réalisé aux consultations de suivi à S4, S8 et S16. Résultats : Parmi les 60 patients, 36 (60%) ont eu au moins un effet indésirable de grade ? II et 9 (15%) de grade III. La valeur moyenne de la concentration plasmatique était de 4725,28ng/mL avec une forte variabilité interindividuelle. La concentration plasmatique moyenne chez les patients ayant présenté un effet indésirable de grade III était significativement supérieure que chez les autres patients (p=0,0218), CHC) avancé. L'impact sur la survie des patients est faible et les effets secondaires invalidants fréquents conduisant à de nombreuses interruptions thérapeutiques ,